ExcelMab Inc.

ExcelMab Inc. is a clinical stage biotech company that focuses on Immuno-Oncology and develops next-generation bispecific antibody drugs to help cancer patients who have failed standard care treatment. The company’s innovative bispecific platform provides a better solution for much safer and more efficacious T-cell engagers.
ExcelMab has been awarded as one of the Top 10 leading BsAb companies in China and its technology platform was rated as one of the best BsAb platforms in China by Boston Consulting Group.
To date, ExcelMab has developed more than 10 BsAb molecules in its pipeline with two most advanced molecules currently in Phase I clinical trials. All molecules showed strong anti-tumor activity in various animal models. According to the non-human primate tox studies, those molecules demonstrated much lower toxicity compared to that of peer molecules. The company is looking for the international partners to co-develop or license its assets and accelerate the development process.